A new randomized trial conducted in an NHS setting in England has found that psilocybin-assisted therapy may be feasible for people with treatment-resistant depression, with early results suggesting improved depressive symptoms compared with placebo. The study, published in Nature Medicine, was designed as a two-arm, double-blind, randomized, placebo-controlled feasibility trial with six weeks of follow-up.
The research was carried out at one NHS site in the UK and enrolled adults aged 25 to 80 with major depressive disorder who had not responded adequately to at least two antidepressant treatments, or one antidepressant and one psychotherapy trial. Participants received a single 25-mg dose of psilocybin or placebo alongside preparation, dosing support and integration therapy.
What the trial found
According to the study authors, the active-treatment group showed significantly greater improvements in depressive symptoms than the placebo group, with effects maintained at three-week and six-week follow-up. The trial also reported that the treatment was well tolerated, with adverse events mostly mild and resolving by the end of the study.
At the same time, the researchers stressed that the findings are preliminary. They noted that blinding was not fully maintained, since many participants correctly guessed which treatment they had received, and they said larger and longer studies are needed to confirm the durability of the effects.
Why the NHS setting matters
The trial was delivered in a public healthcare environment, making it one of the first randomized studies to test psilocybin-assisted therapy for treatment-resistant depression in an NHS context in England. The investigators said this setting offers important information about how such a treatment might work in real-world public mental health services if licensing and funding arrangements are eventually approved.
They also reported that recruitment and retention were strong, suggesting that the study design was workable in routine care conditions. The team said this supports the development of larger efficacy trials in public mental health settings.
For now, the results add to growing interest in psychedelic-assisted treatments while leaving major questions unanswered about long-term benefit, cost-effectiveness and implementation. The researchers concluded that psilocybin could become a future option for patients with severe, chronic depression, but only if later trials confirm both clinical value and safety.
Source: Nature Medicine trial report
Photo source: AI-generated or edited image
